Press releaseGlobe Newswire
Sutro Biopharma
STRO · NASDAQ
$11.54+$0.285 (+2.53%)TodayMarket closed ·
Prev close $11.25
Latest news
- Press releaseGlobe Newswire
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
- NewsVandana Singh
Why is Sutro Biopharma Stock Falling On Wednesday?
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- NewsAvi Kapoor
Gold Gains 1%; Performance Food Group Shares Fall After Q4 Results
- Press releaseGlobe Newswire
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
- NewsAvi Kapoor
XP Posts Downbeat Q1 Earnings, Joins Akamai Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
- Press releaseGlobe Newswire
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
- Press releaseGlobe Newswire
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
- Press releaseGlobe Newswire
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseGlobe Newswire
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering
- Press releasePRNewswire
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
- Press releaseGlobe Newswire
Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Press releaseGlobe Newswire
Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors
- Press releaseGlobe Newswire
Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day
- Press releaseGlobe Newswire
Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights
- Press releaseGlobe Newswire
Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releasePRNewswire
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseGlobe Newswire
Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights
- Press releaseGlobe Newswire
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
- Press releaseGlobe Newswire
Sutro Biopharma to Participate in Upcoming Investor Conferences
- Press releasePRNewswire
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty
- News
Demystifying Sutro Biopharma: Insights From 4 Analyst Reviews
- Press releaseGlobe Newswire
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
- Press releaseGlobe Newswire
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsVandana Singh
Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline
- NewsAvi Kapoor
Dow Jumps Over 600 Points; US Consumer Sentiment Tumbles In March
- NewsAvi Kapoor
Nasdaq Surges 1.5%; Ulta Beauty Posts Upbeat Results
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseGlobe Newswire
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights
- Press releaseGlobe Newswire
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline
- Press releaseGlobe Newswire
Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
- Press releaseGlobe Newswire
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- News
Expert Outlook: Sutro Biopharma Through The Eyes Of 6 Analysts
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.